 Sanchayita Sen
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shock, Hemorrhagic | 6 | 2023 | 202 | 2.310 |
Why?
| | Blood Coagulation Disorders | 6 | 2025 | 196 | 1.430 |
Why?
| | Proteomics | 8 | 2026 | 1183 | 1.190 |
Why?
| | Wounds and Injuries | 5 | 2026 | 960 | 1.050 |
Why?
| | Capillary Permeability | 2 | 2023 | 132 | 0.950 |
Why?
| | Neutrophils | 10 | 2022 | 1118 | 0.880 |
Why?
| | Calcium | 4 | 2023 | 1182 | 0.850 |
Why?
| | Endothelial Cells | 4 | 2023 | 864 | 0.800 |
Why?
| | Fibrinolysis | 3 | 2025 | 164 | 0.780 |
Why?
| | Hypocalcemia | 1 | 2023 | 38 | 0.780 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2022 | 85 | 0.760 |
Why?
| | Serpins | 1 | 2022 | 28 | 0.750 |
Why?
| | Complement C4 | 1 | 2022 | 26 | 0.730 |
Why?
| | Neutrophil Activation | 6 | 2006 | 84 | 0.720 |
Why?
| | Brain Injuries, Traumatic | 3 | 2023 | 451 | 0.720 |
Why?
| | Pericytes | 1 | 2022 | 37 | 0.710 |
Why?
| | Balloon Occlusion | 1 | 2022 | 39 | 0.700 |
Why?
| | Calcium Signaling | 1 | 2023 | 243 | 0.700 |
Why?
| | Blast Injuries | 1 | 2022 | 62 | 0.700 |
Why?
| | Interleukin-8 | 1 | 2022 | 269 | 0.690 |
Why?
| | Arginine | 1 | 2022 | 238 | 0.680 |
Why?
| | Hemolysis | 1 | 2022 | 242 | 0.660 |
Why?
| | Interleukin-10 | 1 | 2022 | 310 | 0.650 |
Why?
| | Astrocytes | 1 | 2022 | 228 | 0.630 |
Why?
| | Endothelium, Vascular | 2 | 2023 | 949 | 0.620 |
Why?
| | Saline Solution, Hypertonic | 4 | 2022 | 43 | 0.590 |
Why?
| | Endovascular Procedures | 1 | 2022 | 385 | 0.510 |
Why?
| | Brain Injuries | 1 | 2022 | 506 | 0.500 |
Why?
| | Proto-Oncogene Proteins c-hck | 1 | 2016 | 1 | 0.500 |
Why?
| | Protein Kinase C | 2 | 2016 | 250 | 0.490 |
Why?
| | Lysophosphatidylcholines | 1 | 2016 | 23 | 0.490 |
Why?
| | Protein Kinase C-delta | 1 | 2016 | 45 | 0.480 |
Why?
| | NADPH Oxidases | 1 | 2016 | 120 | 0.470 |
Why?
| | Tissue Plasminogen Activator | 2 | 2023 | 244 | 0.450 |
Why?
| | Thrombelastography | 5 | 2025 | 190 | 0.410 |
Why?
| | Multiple Organ Failure | 3 | 2022 | 119 | 0.400 |
Why?
| | NF-kappa B | 9 | 2017 | 657 | 0.400 |
Why?
| | Cytokines | 10 | 2022 | 2045 | 0.390 |
Why?
| | Protein C | 2 | 2023 | 53 | 0.380 |
Why?
| | Cell Membrane | 1 | 2016 | 706 | 0.370 |
Why?
| | Swine | 3 | 2023 | 828 | 0.340 |
Why?
| | Thrombosis | 2 | 2026 | 396 | 0.320 |
Why?
| | Inflammation | 6 | 2026 | 2870 | 0.320 |
Why?
| | Enzyme Activation | 7 | 2016 | 762 | 0.300 |
Why?
| | Resuscitation | 2 | 2022 | 310 | 0.290 |
Why?
| | Databases, Protein | 3 | 2018 | 89 | 0.290 |
Why?
| | Hemorrhage | 3 | 2022 | 813 | 0.290 |
Why?
| | Cells, Cultured | 7 | 2023 | 4110 | 0.270 |
Why?
| | Epithelial Cells | 3 | 2017 | 1106 | 0.260 |
Why?
| | Receptors, Immunologic | 2 | 2005 | 206 | 0.250 |
Why?
| | Histones | 2 | 2022 | 663 | 0.250 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 106 | 0.240 |
Why?
| | Receptors, Cell Surface | 2 | 2004 | 370 | 0.220 |
Why?
| | Signal Transduction | 7 | 2017 | 5185 | 0.220 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2005 | 56 | 0.220 |
Why?
| | Lipopolysaccharides | 6 | 2006 | 854 | 0.220 |
Why?
| | Proto-Oncogene Proteins | 3 | 2005 | 619 | 0.220 |
Why?
| | Membrane Glycoproteins | 2 | 2004 | 496 | 0.210 |
Why?
| | Oxidants | 2 | 2004 | 103 | 0.210 |
Why?
| | Humans | 21 | 2026 | 144667 | 0.210 |
Why?
| | TRPV Cation Channels | 1 | 2023 | 43 | 0.200 |
Why?
| | Phosphorylation | 5 | 2016 | 1704 | 0.200 |
Why?
| | Inflammation Mediators | 2 | 2025 | 503 | 0.190 |
Why?
| | Protein Transport | 4 | 2016 | 437 | 0.190 |
Why?
| | Lung | 4 | 2017 | 4089 | 0.190 |
Why?
| | Arginase | 1 | 2022 | 25 | 0.190 |
Why?
| | Thrombophilia | 1 | 2023 | 89 | 0.190 |
Why?
| | Tight Junction Proteins | 1 | 2022 | 15 | 0.180 |
Why?
| | Citrulline | 1 | 2022 | 46 | 0.180 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2022 | 76 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2016 | 532 | 0.180 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 111 | 0.180 |
Why?
| | Dust | 1 | 2022 | 101 | 0.180 |
Why?
| | Multiple Trauma | 1 | 2023 | 121 | 0.180 |
Why?
| | Hydrogen Peroxide | 1 | 2003 | 334 | 0.180 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 380 | 0.180 |
Why?
| | Mice, Inbred BALB C | 8 | 2006 | 1251 | 0.180 |
Why?
| | Endotoxins | 1 | 2022 | 218 | 0.180 |
Why?
| | Animals | 14 | 2023 | 37948 | 0.180 |
Why?
| | Data Curation | 2 | 2018 | 21 | 0.170 |
Why?
| | Male | 15 | 2026 | 72431 | 0.160 |
Why?
| | Plasma | 1 | 2022 | 223 | 0.160 |
Why?
| | Erythrocyte Transfusion | 1 | 2022 | 226 | 0.160 |
Why?
| | Anti-Inflammatory Agents | 1 | 2022 | 477 | 0.140 |
Why?
| | Complement Activation | 1 | 2022 | 409 | 0.140 |
Why?
| | Water | 1 | 2022 | 468 | 0.140 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 4 | 2006 | 265 | 0.140 |
Why?
| | Validation Studies as Topic | 1 | 2017 | 23 | 0.130 |
Why?
| | Protein Conformation | 2 | 2018 | 935 | 0.130 |
Why?
| | Nitric Oxide | 1 | 2022 | 894 | 0.130 |
Why?
| | Vocabulary, Controlled | 1 | 2018 | 47 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2006 | 435 | 0.130 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.120 |
Why?
| | Transcription Factor RelA | 4 | 2014 | 85 | 0.120 |
Why?
| | RNA, Messenger | 3 | 2022 | 2815 | 0.120 |
Why?
| | Mice | 10 | 2016 | 18261 | 0.120 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 153 | 0.120 |
Why?
| | Superoxides | 1 | 2006 | 199 | 0.110 |
Why?
| | Toll-Like Receptor 2 | 3 | 2005 | 127 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1742 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 1207 | 0.110 |
Why?
| | Disease Models, Animal | 2 | 2023 | 4539 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 135 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2005 | 171 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 835 | 0.100 |
Why?
| | Injury Severity Score | 1 | 2016 | 602 | 0.100 |
Why?
| | Lung Injury | 1 | 2016 | 236 | 0.100 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1363 | 0.100 |
Why?
| | Adult | 5 | 2026 | 40489 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2014 | 390 | 0.090 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 601 | 0.090 |
Why?
| | Phospholipases A2, Secretory | 1 | 2012 | 14 | 0.090 |
Why?
| | Kringles | 2 | 2006 | 5 | 0.090 |
Why?
| | Cell Movement | 2 | 2017 | 959 | 0.090 |
Why?
| | Urokinase-Type Plasminogen Activator | 2 | 2006 | 25 | 0.090 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2012 | 129 | 0.090 |
Why?
| | Proteins | 1 | 2017 | 1016 | 0.080 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 820 | 0.080 |
Why?
| | Protein Binding | 1 | 2016 | 2243 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 971 | 0.080 |
Why?
| | Mice, Knockout | 1 | 2016 | 3109 | 0.070 |
Why?
| | Metabolomics | 2 | 2026 | 724 | 0.070 |
Why?
| | Cell Nucleus | 4 | 2017 | 592 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2005 | 287 | 0.070 |
Why?
| | Peptidoglycan | 2 | 2005 | 28 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1468 | 0.070 |
Why?
| | Female | 5 | 2026 | 78304 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2016 | 3603 | 0.070 |
Why?
| | Toll-Like Receptor 4 | 3 | 2005 | 277 | 0.070 |
Why?
| | Bronchioles | 1 | 2016 | 29 | 0.060 |
Why?
| | Toll-Like Receptors | 2 | 2004 | 193 | 0.060 |
Why?
| | Middle Aged | 4 | 2026 | 35971 | 0.060 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 98 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2006 | 2184 | 0.060 |
Why?
| | Integrin alphaVbeta3 | 1 | 2005 | 20 | 0.060 |
Why?
| | Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2005 | 15 | 0.060 |
Why?
| | I-kappa B Kinase | 3 | 2006 | 51 | 0.060 |
Why?
| | Drug Synergism | 2 | 2006 | 352 | 0.060 |
Why?
| | src Homology Domains | 1 | 2005 | 35 | 0.060 |
Why?
| | Up-Regulation | 2 | 2005 | 848 | 0.060 |
Why?
| | Protein Kinases | 2 | 2004 | 314 | 0.050 |
Why?
| | HMGB1 Protein | 1 | 2005 | 51 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2012 | 923 | 0.050 |
Why?
| | Chemokine CXCL2 | 1 | 2004 | 41 | 0.050 |
Why?
| | Fibrinogen | 1 | 2025 | 181 | 0.050 |
Why?
| | Biomarkers | 2 | 2026 | 4261 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2003 | 79 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 64 | 0.050 |
Why?
| | Chemokines | 1 | 2004 | 218 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 616 | 0.050 |
Why?
| | Random Allocation | 1 | 2023 | 366 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2003 | 321 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 106 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2023 | 268 | 0.040 |
Why?
| | Active Transport, Cell Nucleus | 2 | 2006 | 120 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2005 | 2922 | 0.040 |
Why?
| | Mitochondria | 1 | 2016 | 984 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2026 | 915 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2660 | 0.030 |
Why?
| | Anticoagulants | 1 | 2023 | 729 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2026 | 2942 | 0.030 |
Why?
| | Interferon Regulatory Factor-1 | 1 | 2017 | 17 | 0.030 |
Why?
| | Chemokine CCL5 | 1 | 2017 | 40 | 0.030 |
Why?
| | Sequence Analysis, Protein | 1 | 2017 | 33 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2017 | 66 | 0.030 |
Why?
| | Chemotaxis | 1 | 2017 | 123 | 0.030 |
Why?
| | Microcirculation | 1 | 2017 | 141 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2003 | 1338 | 0.030 |
Why?
| | Paraquat | 1 | 2006 | 13 | 0.030 |
Why?
| | Phosphoserine | 1 | 2006 | 25 | 0.030 |
Why?
| | Leukocytes | 1 | 2017 | 294 | 0.030 |
Why?
| | User-Computer Interface | 1 | 2017 | 165 | 0.030 |
Why?
| | Spleen | 1 | 2017 | 510 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 174 | 0.030 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2017 | 346 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 5957 | 0.020 |
Why?
| | Internet | 1 | 2017 | 698 | 0.020 |
Why?
| | Models, Molecular | 1 | 2017 | 1610 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 407 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 503 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2847 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 973 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1161 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2017 | 1984 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2821 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1301 | 0.020 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 341 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5570 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2019 | 0.020 |
Why?
| | Protein Kinase C beta | 1 | 2005 | 21 | 0.010 |
Why?
| | Protein Kinase C-alpha | 1 | 2005 | 37 | 0.010 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2004 | 49 | 0.010 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2004 | 49 | 0.010 |
Why?
| | alpha-Tocopherol | 1 | 2004 | 32 | 0.010 |
Why?
| | Enzyme Stability | 1 | 2004 | 73 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3523 | 0.010 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2004 | 40 | 0.010 |
Why?
| | I-kappa B Proteins | 1 | 2004 | 74 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1046 | 0.010 |
Why?
| | Acetylcysteine | 1 | 2004 | 136 | 0.010 |
Why?
| | Antibodies | 1 | 2005 | 396 | 0.010 |
Why?
| | Antioxidants | 1 | 2004 | 546 | 0.010 |
Why?
|
|
Sen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|